Trial Profile
Efficacy and safety of everolimus (Certican) plus once-daily prolonged-release tacrolimus (Graceptor) combination therapy in living donor kidney transplantation: Open-label, multicenter, randomized controlled trial.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2013
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Mycophenolate mofetil; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 07 Oct 2013 New trial record